약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
Table. 2. Pharmacokinetic parameters of amifampridine and 3-N-acetylamifampridine after oral administration of amifampridine (2 mg/kg) in control (n=5) and acetaminophen-treated rats (n=7).

Data are expressed as means±SDs.

Pharmacokinetic parameters Amifampridine 3-N-acetylamifampridine
Control Acetaminophen-treated Control Acetaminophen-treated
Cmax (μg/mL) 0.07333±0.03190 000.2028±0.0683** 0.7812±0.1647 000.5270±0.1026**
Tmax (min) 29.00±35.60 38.57±27.19 72.00±40.25 0248.6±171.2*
AUClast (μg×min/mL) 9.661±1.124 0039.57±9.02*** 199.3±25.9 172.4±33.5
AUCinf (μg×min/mL) 10.16±1.44 0045.66±9.51*** 224.6±50.7 231.5±51.6
t1/2 (min) 96.59±25.20 126.0±16.6 123.2±42.2 220.5±98.1
MRT (min) 158.5±54.4 191.8±25.3 231.2±70.4 0384.8±110.1*
CL/F (mL/min/kg) 200.1±28.9 0045.36±9.38*** - -
Vd/F (mL/kg) 27290±4360 0008218±2001*** - -
CLr (mL/min) 3.135±0.889 2.441±0.913 4.886±0.490 4.573±1.484
AUCm/AUCp - - 21.99±2.33 0005.297±1.934***

AUCm/AUCp, AUCinf ratio of 3-N-acetylamifampridine to amifampridine; CLr, renal clearance.

*p<0.05, **p<0.01 and ***p<0.001 compared with control rats

Yakhak Hoeji 2024;68:98-104 https://doi.org/10.17480/psk.2024.68.2.98
© 2024 Yakhak Hoeji